{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-058191","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.077545+00:00","generated_at":"2026-06-02T02:00:49.491054+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Precision BioSciences Q1 2024 revenue $17.6M, net income $8.6M; cash runway into H2 2026","bullets":["Revenue $17.6M (up from $8.8M YoY); net income $8.6M vs loss $25.1M in Q1 2023.","Cash and equivalents $137.8M; cash runway extended into H2 2026 via $40M equity offering.","PBGENE-HBV on track for IND/CTA filing in 2024; PBGENE-PMM expected in 2025.","iECURE's OTC gene editing program opened enrollment in UK, first in vivo ARCUS trial.","Regained rights to three preclinical programs (DMD, liver, CNS) from Prevail collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-058191","json":"https://secwatch.observer/filing/0000950170-24-058191.json","markdown":"https://secwatch.observer/filing/0000950170-24-058191.md","text":"https://secwatch.observer/filing/0000950170-24-058191.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024058191/0000950170-24-058191-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024058191/dtil-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:00:49.491054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}